ظاهرة دفن الكتب عند الرواة، وأثرها على الراوي والرواية: دراسة استقرائية تحليلية за авторством Alasasmeh , Adel Harb Bashir

Предмети: Отримати повний текст

Figure S1 from Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer за авторством Samuel Rosner (15054884)

Предмети:

Supplementary Tables 1-8 from Alternating 17β-Estradiol and Aromatase Inhibitor Therapies Is Efficacious in Postmenopausal Women with Advanced Endocrine-Resistant ER⁺ Br... за авторством Gary N. Schwartz (16005870)

Предмети:

Supplementary Figure S2 from A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors: Two-Year Outcomes за авторством Benjamin K. Wilke (15055112)

Предмети:

Supplementary Figure S1 from A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors: Two-Year Outcomes за авторством Benjamin K. Wilke (15055112)

Предмети:

Supplementary Figure 1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovari... за авторством Stephanie L. Wethington (16354020)

Предмети:

Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma за авторством Qingsheng Xu (17078830)

Предмети:

Supplementary Table S2 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carci... за авторством John A. Ligon (15024477)

Предмети:

Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma за авторством Qingsheng Xu (17078830)

Предмети:

Supplemental Figure S4 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refrac... за авторством Ibrahim Aldoss (15055961)

Предмети:

Figure 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors за авторством Kristoffer Staal Rohrberg (15009138)

Предмети:

Figure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors за авторством Kristoffer Staal Rohrberg (15009138)

Предмети:

Table 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors за авторством Kristoffer Staal Rohrberg (15009138)

Предмети:

Supplemental Figure S1 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refrac... за авторством Ibrahim Aldoss (15055961)

Предмети:

Table 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors за авторством Kristoffer Staal Rohrberg (15009138)

Предмети:

Figure S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors за авторством Kristoffer Staal Rohrberg (15009138)

Предмети:

Table 4 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors за авторством Kristoffer Staal Rohrberg (15009138)

Предмети:

Supplemental Figure S2 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refrac... за авторством Ibrahim Aldoss (15055961)

Предмети:

Supplemental Figure S5 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refrac... за авторством Ibrahim Aldoss (15055961)

Предмети:

Supplemental Figure S3 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refrac... за авторством Ibrahim Aldoss (15055961)

Предмети: